BACKGROUND: Practice guidelines reflect published literature. Because of the ever
changing literature base, it is necessary to update and revise guideline recommendations …

Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to
reduce platelet reactivity and to prevent thrombotic events in patients treated with …

ESC Guidelines 3002 recommendations. To implement the guidelines, condensed pocket
guidelines versions, summary slides, booklets with essential messages, and an electronic …

Background It is unknown whether patients undergoing primary percutaneous coronary
intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors. Methods …

Context High platelet reactivity while receiving clopidogrel has been linked to cardiovascular
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …

Content Clopidogrel, one of the most commonly prescribed medications, is a prodrug
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …

Background The relation between platelet reactivity and stent thrombosis, major bleeding,
and other adverse events after coronary artery implantation of drug-eluting stents has been …

1.1. Methodology and Evidence Review The standing guideline writing committee along
with the parent Task Force identified trials and other key data through October 2011 that may …

The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

Background Patients' responses to oral antiplatelet therapy are subject to variation. Bedside
monitoring offers the opportunity to improve outcomes after coronary stenting by …